LAG3+ CD8+ T cell Subset Drives HR+/HER2- Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell Therapy
LAG3+ CD8+ T 细胞亚群驱动双特异性抗体武装活化 T 细胞疗法降低 HR+/HER2- 乳腺癌的发生率
期刊:
影响因子:
doi:10.1101/2025.01.04.631323
Barnes, Robert Weldon; Thakur, Archana; Onengut-Gumuscu, Suna; Lum, Lawrence G; Dolatshahi, Sepideh
肿瘤
T细胞
HER2
肿瘤免疫
LAG3
CD8
乳腺癌
细胞生物学
